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Abstract
Background: Botulism is caused by botulinum neurotoxins (BoNTs), extremely toxic proteins which can induce
respiratory failure leading to long-term intensive care or death. Treatment for botulism includes administration of
antitoxins, which must be administered early in the course of the intoxication; therefore, rapid determination of
human exposure to BoNT is an important public health goal. In previous work, our laboratory reported on
Endopep-MS, a mass spectrometry-based activity method for detecting and differentiating BoNT/A, /B, /E, and /F in
clinical samples. We also demonstrated that antibody-capture is effective for purification and concentration of
BoNTs from complex matrices such as clinical samples. However, some antibodies inhibit or neutralize the
enzymatic activity of BoNT, so the choice of antibody for toxin extraction is critical.
Results: In this work, we evaluated 24 anti-BoNT/B monoclonal antibodies (mAbs) for their ability to inhibit the in
vitro activity of BoNT/B1, /B2, /B3, /B4, and /B5 and to extract those toxins. Among the mAbs, there were
significant differences in ability to extract BoNT/B subtypes and inhibitory effect on BoNT catalytic activity. Some of
the mAbs tested enhanced the in vitro light chain activity of BoNT/B, suggesting that BoNT/B may undergo
conformational change upon binding some mAbs.
Conclusions: In addition to determining in vitro inhibition abilities of a panel of mAbs against BoNT/B1-/B5, this
work has determined B12.2 and 2B18.2 to be the best mAbs for sample preparation before Endopep-MS. These
mAb characterizations also have the potential to assist with mechanistic studies of BoNT/B protection and
treatment, which is important for studying alternative therapeutics for botulism.
Background
Botulism is a disease which can be fatal if untreated and
is caused by exposure to any one of the highly toxic
protein family known as botulinum neurotoxins
(BoNTs). In vivo, BoNT cleaves proteins necessary for
nerve signal transmission. This enzymatic cleavage
results in the inhibition of the nerve impulse, leading to
flaccid paralysis of the victim which can affect the lungs
and may necessitate ventilator support. Treatment of
the botulism patient involves administration of thera-
peutic immunoglobulin and is most effective when
administered within 24 h of toxin exposure [1]. Due to
the extreme toxicity, global availability, and ease of pre-
paration of BoNT, it is considered a likely agent for bio-
terrorism [2].
Previously, our laboratory reported in several publica-
tions on the development of the Endopep-MS method
as an assay for BoNT detection and serotype differentia-
tion [3,4]. This method can detect all seven known
BoNT serotypes and involves incubating BoNT with a
peptide substrate that mimics each toxin’s natural in
vivo neuronal protein target. The presence of a particu-
lar BoNT serotype is demonstrated by mass spectro-
metric detection of the peptide cleavage products
corresponding to their specific toxin-dependent location.
Endopep-MS currently uses an antibody-affinity concen-
tration/purification step before the enzymatic reaction
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any medium, provided the original work is properly cited.with the substrate, and the choice of antibody is critical
for the success of this assay [5]. We previously reported
that polyclonal anti-BoNT binding could interfere with
the activity of BoNT as measured by Endopep-MS [5].
We also reported on the success of using monoclonal
(mAb) anti-BoNT/A to detect multiple subtypes of
BoNT/A [6,7].
Similar to the other BoNT serotypes, BoNT/B consists
of a heavy chain (HC) of approximately 100,000 daltons
and a light chain (LC) of about 50,000 daltons. The
heavy chain is mainly responsible for both receptor
binding by its C-terminal (CT) binding domain [8,9]
(HC) and the delivery of the catalytic light chain (LC) to
its target inside the neuron by way of its N-terminal
translocation domain (HN)[10]. Although the LC is
responsible for the specific toxicity, it requires the heavy
chain to enter the target cell and produce this toxic
activity in vivo. As with most of the other BoNT sero-
types, BoNT/B exhibits genetic and amino acid variance
within the serotype, and this variance is defined as a
subtype. BoNT/B is currently defined as consisting of
the /B1, /B2, /B3, /B4, /B5, and /B6 subtypes. [11,12]. At
the amino acid composition level, the variance among
all the BoNT/B is 7% or less, but this degree of variance
can affect binding of the toxin to some of the anti-
BoNT/B mAbs as shown before [13]. So, it is important
to select cross reactive mAbs which are able to detect
all toxin subtypes, because an outbreak of BoNT/B
botulism may be attributed to more than just the famil-
iar “common” subtype.
Previously, our laboratory demonstrated that the
Endopep-MS assay can be used to detect all currently
known available subtypes of BoNT/B [7,14]. The goal of
this work is to evaluate a panel of mAbs for their inhibi-
tory and extraction abilities, thereby optimizing assay
sensitivity with all BoNT/B subtypes available to us for
t e s t i n g .H e r e ,w ee v a l u a t e dap a n e lo f2 4f u l l yh u m a n
monoclonal anti-BoNT/B mAbs for their ability to inhi-
bit the in vitro light chain activity of BoNT/B1, /B2, /B3,
/B4, or /B5. BoNT/B6 was unavailable to us for testing.
A d d i t i o n a l l y ,w ee v a l u a t e dt h es a m ea n t i b o d yp a n e lf o r
their ability to extract any of the available subtypes of
BoNT/B. Our data show that there were significant dif-
ferences among those mAbs in their ability to extract
different BoNT/B subtypes, and their inhibitory effects
on BoNT/B catalytic activity. Surprisingly, some of the
mAbs appeared to enhance the light chain enzymatic
activity of some subtypes of BoNT/B, a phenomenon
that has been reported for BoNT/A, but not yet for
BoNT/B [15]. Such differences could be explained in
part through analyzing the epitopes of the mAbs and
the amino acid sequences of each subtype of BoNT/B.
Our results indicate which mAbs have the optimal prop-
erties for use in the Endopep-MS detection of BoNT/B.
Methods
Materials
Botulinum neurotoxin is very toxic and must be handled
with extreme care and appropriate safety measures. All
neurotoxins were handled in a level 2 biosafety cabinet
equipped with HEPA filters. Commercially purified
BoNT/B1 (strain Okra) was purchased from Metabiolo-
gics (Madison, WI). Crude culture supernatants repre-
senting various BoNT/B subtypes [11] were produced by
incubating subcultures of each strain for 5 days at 30-
35°C. Information on the strains used in these studies is
listed in Table 1. After centrifugation, supernatants were
removed and filtered through 0.22 μm filters. The fil-
tered supernatants were tested for upper limits of toxi-
city, which indicated that the toxins were all present at
concentrations of ≤ 10 μg/mL. Some of the preparations
were titered to determine lethality in mouseLD50
(mLD50)/mL as in reference 6.
Dynabeads
® Protein G was purchased from Invitrogen
( C a r l s b a d ,C A )a t1 . 3g / c m
3 in phosphate-buffered sal-
ine, pH 7.4, containing 0.1% Tween
®-20 and 0.02%
sodium azide. Except where indicated, all chemicals
were from Sigma-Aldrich (St. Louis, MO). Peptides were
synthesized by Los Alamos National Laboratory (Los
Alamos, NM) and are identical to those reported pre-
viously [3-5,7,14]. Specifically, the peptide substrate has
the sequence LSELDDRADALQAGASQFESSAAKLKR-
KYWWKNLK and the internal standard peptide (ISTD)
has the sequence LSELDDRADALQAGASQ where A
indicates a +7 mass increase to a naturally occurring
alanine.
Preparation of Monoclonal Antibodies
All the mAbs used in this report were first selected or
engineered as antibody leads from scFv or Fab display
immune libraries and converted into full-length human
IgG1 as previously reported [13,16]. Specifically, mAb
A12 and 6A12 were first selected from a scFv phagemid
library [17,18] before systematic characterization in the
yeast display format. The leads of all other 22 mAbs
were generated directly from yeast display immune
libraries either in the scFv or Fab format [[13,16], Geren
IN, Garcia-Rodriguez C, Lou J, Conrad F, Fan F, et al:
Table 1 Strain information on culture supernatants used
for this study.
Sample Strain NCBI accession #
B1 (proteolytic) Okra AB232927
B2 (proteolytic) 213B ABM73972
B3 (proteolytic) CDC 795 EF028400
B4 (nonproteolytic) Eklund 17B EF051570
B5 (bivalent) An436 EF028397
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types A and B from immune yeast displayed antibody
libraries, submitted]. Some mAbs [19] (B12.1, B12.2,
1B12.3, 1B12.4, B8.1, B6.1, 2B18.1, 2B18.2, 2B18.3,
B11E8, 1B22.4, 1B10.1, and 2B25.1) were engineered
toward higher affinity or better cross reactivity [20] for
most available BoNT/B subtypes, through chain shuf-
fling using a scFv or Fab yeast display system [13,19],
before they were converted into the IgG format which
consists of the human gamma 1 constant region and the
human kappa or lambda constant region. Stable CHO
DG44 cell lines were established for each of the antibo-
dies and IgG was purified from cell culture supernatant
using a protein G affinity column. The monovalent KD
was determined for each IgG using kinetic exclusion
analysis (Kinexa). All the purified IgG were stored at
-70°C until application.
BoNT/B Inhibition Experiments
A2 - μL solution containing 30 ng of each titered IgG
was added to a 2-μL solution containing 25 mLD50 of
BoNT/B1, or estimated levels of 10-25 mLD50 of/B2,/
B3,/B4, or/B5. The mixtures were incubated for 1 h at
room temperature with no agitation. Then, 16 μLo fa
reaction mixture (0.05 M Hepes [pH 7.3], 25 mM
dithiothreitol, 20 μMZ n C l 2, 1 mg/mL bovine serum
albumin, and 50 pmol/μL of peptide substrate) was
added to the mixture. All samples then were incubated
a t3 7 ° Cf o r4hw i t hn oa g i t a t i o n .A l la s s a y sw e r ep e r -
formed in duplicate and results were averaged.
BoNT/B Extraction Experiments
The IgG was immobilized and cross-linked to the Dyna-
beads
® Protein G as described in previous publications
[5-7,14]. An aliquot of 20 μL of antibody-coated beads
was mixed for 1 h with a 0.5-mL solution containing 25
mLD50 of BoNT/B1, or estimated levels 10-25 mLD50
of/B2-/B5. The solution was prepared by spiking
approximately 625 mLD50 of either BoNT/B1, /B2, /B3,
/B4, or /B5 into 12.5 mL of phosphate-buffered saline
with 0.01% Tween (PBST) buffer. After mixing for 1 h
with constant agitation at room temperature, the beads
were washed twice in 1 mL each of PBST and then
washed once in 100 μL of water. The beads were recon-
stituted in a 20-μL solution containing 0.05 M Hepes
(pH 7.3), 25 mM dithiothreitol, 20 μM ZnCl2,1m g / m L
bovine serum albumin, and 50 pmol/μL of peptide sub-
strate. All samples then were incubated at 37°C for 4 h
with no agitation. All assays were performed in dupli-
cate and results were averaged.
Estimation of BoNT/B2-/B5 Activity
As precise mouse LD50 titer data were unavailable for
the crude toxin extract of BoNT/B2, /B3, /B4, and /B5,
we first estimated the activity of these subtypes by test-
ing 25 mLD50 of BoNT/B1 in a 2 μL volume in parallel
with 2 μL of varying dilutions in water of the crude
extract containing BoNT/B2, /B3, /B4, and /B5. All sam-
ples were then incubated with 18 μL of a reaction mix-
ture (0.05 M Hepes [pH 7.3], 25 mM dithiothreitol, 20
μMZ n C l 2, 1 mg/mL bovine serum albumin, and 50
pmol/μL of peptide substrate) for 4 hr at 37C.
MS Detection
A master mix was created consisting of 9 parts matrix
solution (alpha-cyano-4-hyd r o x yc i n n a m i ca c i d )a t5
mg/mL in 50% acetonitrile, 0.1% trifluoroacetic acid
(TFA), and 10 mM ammonium phosphate) and 1 part
ISTD in water at 5 μM. To 18 μLo ft h i sm a s t e rm i x ,2
μL of each reaction supernatant were added. We
pipetted 0.5 μL of this mixture onto each spot of a 384-
spot matrix-assisted laser desorption/ionization
(MALDI) plate (Applied Biosystems, Framingham, MA).
Mass spectra of each spot were obtained by scanning
from 1100 to 5500 m/z in MS-positive ion reflector
mode on an Applied Biosystems 4800 Proteomics Ana-
lyzer (Framingham, MA). The instrument uses a Nd-
YAG laser at 355 nm, and each spectrum is an average
of 2400 laser shots.
Results
Effect of Antibody Addition on BoNT/B Enzymatic Activity
The mAbs evaluated in this work bound 11 different
epitopes on the BoNT/B HC,H N, or LC (Table 2, Figure
1). Because BoNTs consist of two chains, with one
chain responsible for enzymatic activity (LC) and
another chain (HC) responsible for directing the enzy-
matically active light chain to its target inside the neu-
ron, antibodies reacting with the LC of the toxin may
inhibit the toxin’s activity. Therefore, an inhibition
experiment was performed in which an equal amount of
each antibody was added to the BoNT/B Endopep-MS
reaction. The molar concentration of antibody in all
cases exceeds the molar concentration of toxin by at
least 40- to 70- fold, ensuring that essentially all of the
LC is bound by antibody and that antibody activity is
evaluated separately from antibody affinity.
The inhibition experiment was performed with a panel
of 24 mAbs (Table 2) against BoNT/B1, /B2, /B3, /B4,
or /B5 toxin complexes. As controls, we also performed
the inhibition experiments in the absence of antibodies
and in the presence of CR2, an anti-BoNT/A mAb that
does not cross-react with toxins in the BoNT B serotype
[20]. Table 3 lists the peak area ratios of the native clea-
vage product over the ISTD obtained from the reaction
of these five BoNT/B toxins with all the 25 antibodies
and the no-antibody control reaction. An increase in
peak area ratio indicates a more enzymatically active
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each mAb. Figure 2 is a graph of the change in enzy-
matic activity of proteolytic BoNT/B1 and /B2 by anti-
body binding as calculated through the peak area ratios
of each mAb sample compared to the peak area ratio in
the absence of any antibodies.
The inhibition studies show that the catalytic activity
of BoNT/B1 toxin is inhibited to some degree in the
presence of only a portion of the tested mAbs (Table 3,
F i g u r e2 ) .T h i si si nm a r k e dc o n t r a s tt ow h a tw a s
observed when studying a panel of BoNT/A mAbs in
which the light chain catalytic activity of all subtypes of
BoNT/A tested were inhibited in the presence of any
mAb tested [6]. Many of the mAbs tested actually
increased the LC catalytic activity of BoNT/B1 over the
control with no antibodies added to the reaction. For
example, after mass spectrometric analysis, it is clear
that there was a NT cleavage product at 1759.9 m/z in
the reaction containing either the mAb 6A12 or no anti-
body (Figure 3A vs 3B). Both reactions contained the
same amount of ISTD at m/z 1766.9, so by comparison
of the size of the 1766.9 peaks with the size of the
1759.9 peaks, we could determine that the amount of
NT cleavage product at m/z 1759.9 was much larger
with the mAb 6A12 (Figure 3A) reaction than that with
no antibody (Figure 3B). Of note, mAbs that increased
LC catalytic activity tended to bind either the HC or the
HN (Table 2 and Figure 2).
These data indicate that mAb 6A12 serves as an acti-
vator of the LC enzymatic activity of BoNT/B1 toxin;
many of the other mAbs tested also appeared to activate
the LC of the toxin to some degree. However, the
amount of NT cleavage product is much smaller with
the mAb 2B27 reaction (Figure 3C) than those with no
antibody (Figure 3B). This indicated that this antibody
inhibits the activity of BoNT/B1. The sum of the results
for the BoNT/B1 toxin inhibition test indicated that a
number of mAbs inhibited the LC catalytic activity, with
the most inhibitory antibody being mAb 1B10.1. Most
of these inhibitory mAbs bound to the LC. For mAb
1B10.1, there was no cleavage product present at all
(Figure 2). In fact, a separate experiment (data not
Table 2 Affinities, domain specificity, and epitopes of 24 human mAbs to BoNT/B.
mAb BoNT/B epitope KD BoNT/B1 (pM) KD BoNT/B2 (pM) KD BoNT/B3 (pM) KD BoNT/B4 (pM)
6A12 HC epitope 1 5150 NB NB NB
B12.1 HC epitope 1 40.21 15.42 52.28 624.50
B12.2 HC epitope 1 346 90.11 NM NM
1B12.3 HC epitope 1 75.73 57.05 68.1 356.73
1B12.4 HC epitope 1 15.60 27.11 9.39 399
2B30 HC epitope 1 370(scFv) 190(scFv) NB NB
B1.1 HC epitope 2 477(scFv) NB NB NB
B8.1 HC epitope 3 46.03 90.12 NB NM
A12 HC epitope 3 2100 NB NB NB
B11E8 HN epitope 4 6.59 18.1 15.60 NB
1B18.1 HN epitope 5 545 818 976 21
2B18.1 HN epitope 5 63 181 91 312
2B18.2 HN epitope 5 30.82 83.75 228(scFv) 526(scFv)
2B18.3 HN epitope 5 17.4 20.33 128 3108
B6.1 LC epitope 6 6.82 9.18 28.5 9.41
2B24 LC epitope 6 7.8 10.38 5.44 5.96
1B10.1 LC epitope 7 0.33 0.35 1206 0.41
2B27 LC epitope 7-8 165.4 560(scFv) 2320(scFv) 77(scFv)
1B22 LC epitope 8-9 336.1 319.3 221.1 128.6
1B22.4 LC epitope 8-9 139(scFv) 110(scFv) 141(scFv) 129(scFv)
2B25.1 LC epitope 8-9 16.69 53.32 9.07 29.53
2B29 LC epitope 9 856.7 1020 1610 1290
2B23 LC epitope 10 38.07 45.63 54.89 48.23
4B19.1 LC epitope 10 176.1 138.5 115.5 194
Affinities were measured for IgG using flow fluorimetry in a KinExA or for yeast displayed scFv using FACS (indicated as scFv after the KD data). Epitope numbers
identify mAbs whose binding sites on BoNT/B overlap; mAb with the same epitope number cannot bind BoNT/B simultaneously. “NB” means no binding
detected at the highest concentration of toxin (up to 1 μM) tested. “NM” means no measurement was performed for that specific subtype of toxin.
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inhibit the LC enzymatic activity up to 100 mLD50 of
BoNT/B1.
The BoNT/B2 protein differs from BoNT/B1 by 4% at
the amino acid level. Because it is important to under-
stand whether this level of genetic differences results in
inhibition differences with various mAbs, all 24 mAbs
were also examined for their enzymatic inhibition of
BoNT/B2. The data in Table 3 and Figure 2 show that,
despite slight genetic differences, most of the results for
inhibition of BoNT/B2 were similar to that for BoNT/
B1, with the exception of B6.1, 2B29, and 2B18.1. B6.1
is an inhibitor of BoNT/B1 activity, but appears to be
an activator of BoNT/B2 LC activity. mAb 2B29 acts as
an inhibitor of BoNT/B1 enzymatic activity; however, it
does not have this effect on BoNT/B2 activity.
The proteolytic subtype BoNT/B3 also differs from
BoNT/B1 by 4% at the amino acid level, and it differs
from BoNT/B2 by 2%, so we examined the effect of all
24 mAbs against BoNT/B3 as well. The results, depicted
in Figure 4 and Table 3 are comparable to that observed
for BoNT/B1 toxin, with the same exceptions noted on
the BoNT/B2 test (B6.1 and 2B29), as described above.
Additional notable differences include 1B22 and 1B22.4,
which are both inhibitors of BoNT/B1 activity, but had
no effect on BoNT/B3 activity.
Non-proteolytic BoNT/B4 is the most dissimilar
among all the BoNT/B subtypes and differs from BoNT/
B1 by 7% at the amino acid level. This toxin, like all
other BoNT/B, is produced as a single chain neurotoxin,
but unlike other BoNT/B, it remains as a single chain as
opposed to being cleaved into a dichain toxin. Incubat-
ing this toxin with the panel of 24 mAbs yielded much
the same results as with the other BoNT/B subtypes.
This is seen in Figure 4 and Table 3. As with BoNT/B2
and/B3, mAbs B6.1 and 2B29 did not appear to inhibit
this toxin subtype. Additionally, mAbs 2B25.1 and 2B27
also did not appear to inhibit the activity of BoNT/B4
whereas these mAbs inhibited the activity of other
BoNT/B subtypes.
BoNT/B5, produced by bivalent Clostridium strains,
differs from BoNT/B1 by 4% at the amino acid level.
The only differences in activity of this toxin subtype
against the panel of 24 mAbs compared to the results
from the BoNT/B1 activity test were noticed with mAbs
B6.1 and 1B10.1, as seen in Figure 4 and Table 3. B6.1
Figure 1 The X-ray crystal structure of BoNT/B1 with the three
functional domains indicated. Epitopes bound by the 24 mAbs
used in this work are indicated. Epitope placement on each domain
is arbitrary, except for epitope 5 on the HN and epitope 7 on the
LC. Epitope 5 is bound by the 1B18 family of mAbs which bind the
tip of the HN, as indicated (Geren IN, Garcia-Rodriguez C, Lou J,
Conrad F, Fan F, et al: Human monoclonal antibodies to botulinum
neurotoxin types A and B from immune yeast displayed antibody
libraries, submitted). Epitope 7 is bound by 1B10.1, which has been
mapped to the indicated location on the LC (data unpublished).
Table 3 Peak area ratios of the peptide cleavage product
divided by the internal standard peptide obtained from
the Endopep-MS reaction of BoNT/B with its peptide
substrate in the presence of the antibody panel.
Antibody BoNT/B1 BoNT/B2 BoNT/B3 BoNT/B4 BoNT/B5
None 0.43 1.65 0.72 0.48 0.73
CR2 0.38 1.59 0.79 0.51 1.08
6A12 0.78 2.16 0.93 0.35 0.87
A12 0.76 2.11 0.83 0.53 0.96
B12.2 0.68 2.24 0.85 0.53 0.89
B8.1 0.66 2.13 0.95 0.48 1.06
B12.1 0.63 1.75 1.03 0.48 1.30
2B18.2 0.62 1.83 0.8 0.56 1.24
2B24 0.57 1.78 0.74 0.53 1.07
B1.1 0.56 2.31 0.81 0.54 1.72
2B18.1 0.55 1.39 0.88 0.61 1.09
1B18.1 0.51 2.22 1.07 0.68 0.45
2B30 0.50 1.84 1.29 0.93 0.58
2B23 0.46 1.45 0.85 0.56 1.32
B11E8 0.44 2.44 0.89 0.51 0.82
2B18.3 0.44 2.16 0.75 0.64 0.76
1B12.4 0.40 1.28 0.89 0.77 1.18
4B19.1 0.38 1.49 0.92 0.71 0.60
1B22.4 0.37 1.58 0.92 0.28 0.80
1B12.3 0.35 1.31 0.68 0.70 1.07
B6.1 0.32 2.08 0.87 0.32 1.49
1B22 0.31 1.64 1.04 0.27 0.71
2B29 0.30 1.75 0.98 0.42 0.65
2B27 0.28 1.01 0.62 0.24 0.72
2B25.1 0.27 1.01 0.87 0.25 0.70
1B10.1 0 0.02 0.19 0.10 0.65
Five different subtypes of BoNT/B were used, and they include /B1, /B2, /B3,
/B4, and /B5.
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Interestingly, mAb 1B10.1 also had no inhibition effect
on the activity of BoNT/B5, perhaps due to its lower
affinity for BoNT/B5 compared to the other BoNT/B
subtypes (unpublished data).
BoNT/B extraction efficiency
After determining which antibodies were inhibitory
toward the catalytic activity of BoNT/B1-/B5, we wanted
to examine the ability of any of the panel of 24 mAbs in
our assay to extract BoNT/B1-/B5 in the Endopep-MS
assay. Extraction assessed both the ability of the mAb to
bind BoNT/B, reflected by the mAb affinity, as well as
the inhibition of BoNT/B by the mAbs. All mAbs were
used to extract the same level of BoNT/B from a buffer
solution. After extraction, the toxins on the beads were
added to identical reaction mixtures containing peptide
substrate. Upon mass spectrometric analysis, it was
apparent that the mAb B12.2 (Figure 5A), non-extracted
(Figure 5B), and mAb B1.1 (Figure 5C) extracted sam-
ples contained the internal standard at m/z 1766.9, but
only the B12.2 mAb-extracted sample and the non-
extracted control contained N-terminal cleavage product
at m/z 1759.9. Comparing the NT products with ISTDs
shows that the mAb B12.2 antibody-extracted sample
contains more N-terminal cleavage product than the
mAb B1.1 antibody-extracted sample or the non-
extracted control. Because all samples contained the
same amount of internal standard, the generation of a
higher level of cleavage product indicated a greater level
of toxin, a higher activity of toxin, or possibly both for
mAb B12.2 compared to mAb B1.1.
Table 4 contains the peak area ratios of the cleavage
product over the ISTD for 24 BoNT/B mAbs used to
extract BoNT/B1, /B2, /B3, /B4, or /B5. mAbs B1.1 and
1B10.1 yielded no cleavage product, and mAb 1B22.4
yielded minimal cleavage product. As with the inhibition
studies, we also wanted to check extraction efficiency
0
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Figure 2 A graph indicating the % of inhibition in activity of BoNT/B1 (blue) and /B2 (red) following incubation with the antibody
panel. The sample with no antibodies had no inhibition of activity, so the % of inhibition in activity is calculated by dividing the peak area ratio
of the peptide cleavage product over the internal standard peptide of the individual antibody by the peak area ratio of the sample with no
antibodies.
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five BoNT/B subtypes. A number of mAbs that had
good extraction efficiency for BoNT/B1 also had good
extraction efficiency for BoNT/B2-/B5. These include
mAbs 1B18.1, 2B18.1, 2B18.2, 2B18.3, B12.2, and 2B23.
Some antibodies, like mAbs B1.1, 1B10.1, or 1B22.4, had
either poor extraction efficiency or inhibited the enzy-
matic activity of all five BoNT/B subtypes tested. Inter-
estingly, some antibodies (such as mAb B11E8 and
2B30) had good extraction efficiency for four of the five
BoNT/B subtypes tested and appeared to activate these
toxins, but had poor extraction efficiency for BoNT/B4
which is produced by a nonproteolytic bacteria strain. In
the case of B11E8, this can be explained by its inability
to bind to the BoNT/B4 subtype (Table 2).
Discussion
After examining a panel of BoNT/A [6] and BoNT/B
mAbs (this study) we found that there are significant
differences in the ability of the mAbs to inhibit or acti-
vate BoNT. Most importantly, we did not observe acti-
vation of the LC activity by any of the anti-BoNT/A
mAbs, whereas we did observe this with a number of
BoNT/B mAbs. Interestingly, in this study, the majority
of the mAbs that enhanced the enzymatic activity of the
BoNT/B subtypes bound the HC portion of the toxin,
which is not enzymatically active.
The phenomenon of toxin activation by antibody
binding is not a novel one [15], and it is thought that
some mAbs induce a conformational change upon the
structure of the toxin after binding so that the toxin is
induced into an optimal conformation to bind the sub-
strate. It is highly possible that this induced-conforma-
tional change was responsible for the increase in BoNT/
B LC enzymatic activity with some mAbs, particularly
those which did not bind near the enzymatic active site.
It is also important that although a mAb could be an
activator of LC activity in an enzymatic assay, it does
not mean that this mAb would enhance in vivo toxicity.
Not all of the anti-BoNT/B mAbs were LC activators.
For example, mAb 1B10.1 inhibited the LC activity of
four of the five BoNT/B subtypes. Antibody 1B10.1
bound the LC of the toxin (Table 2, Figure 1), and resi-
dues R121, R122, N177, H179, F180, R183, E184, D244,
a n dD 2 4 5o fB o N T / Bc o n t r i b u t et ot h eb i n d i n go f
1B10.1 as mapped [21] using yeast displayed BoNT/B
LC (C. Garcia and J.D. Marks, unpublished data). The
active site of BoNT/B was centered around residue 231,
which is quite close to the epitope for the binding of
mAb 1B10.1. It is highly probable that upon binding of
1B10.1, BoNT/B toxin is no longer able to access the
p e p t i d es u b s t r a t e ,a n di st h e r e f o r ei n a c t i v eu p o nt h e
peptide substrate. This explains the ability of 1B10.1 to
inhibit the enzymatic activity of most BoNT/B subtypes.
Looking at the amino acid similarities of the BoNT/B
subtypes in these residues, we found that only one
mutation existed–the aspartic acid in position 244,
which is negatively charged, is mutated to neutral aspar-
agine in BoNT/B5. This mutation may explain the lower
affinity of mAb 1B10.1 for BoNT/B5 and its lack of
inhibition.
Another inhibitory antibody is 2B27, which bound the
LC of the toxin. The 2B27 epitope overlaps the epitope
of mAb 1B10.1 (Table 2 and Figure 1). This proximity
to the active site of the toxin explains its ability to inhi-
bit the LC activity of this toxin. In fact, most of the
other inhibitory antibodies are also LC binders, presum-
ably because these mAbs interfere with the binding of
the substrate to the toxin. It is important, however, that
not all LC binders inhibit BoNT/B1 enzymatic activity.
mAb 2B23 bound the LC, but had virtually the same
response in enzymatic activity as the control with no
antibody. Although mAb 2B23 bound the LC (Table 2,
Figure 1) the epitope seems to be farther away from the
enzymatic active site, so it does not have an inhibitory
effect on the toxin’s activity.
B6.1 was inhibitory for some BoNT/B subtypes, but
acted as an activator of LC activity for other subtypes.
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Figure 3 Mass spectra of the Endopep-MS BoNT/B1 reaction
with mAb 6A12 (3A), no antibody (3B), or mAb 2B27 (3C). The
peptide cleavage product indicating that BoNT/B1 is present to
some extent in all cases is at m/z 1759.9 and the internal standard
is present at m/z 1766.9.
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Page 7 of 11mAb B6.1 bound the LC of toxin on epitope 6; however,
it did not bind in close proximity to the enzymatic
active site (Figure 1). Therefore, it is possible that B6.1
binding inhibits some BoNT/B not by B6.1 itself block-
ing the peptide substrate from the active site, but rather
by the induced conformational change upon that toxin.
This would result in an altered quaternary structure of
BoNT/B1 and /B4 which has difficulty contacting the
peptide substrate, while the changed conformation of
BoNT/B2, /B3, and /B5 upon mAb B6.1 binding might
have easier access to the substrate, thereby serving as an
activator of LC activity for BoNT/B2, /B3, and /B5. This
phenomenon could also explain the activity of 2B29 and
2B18.1, which also serve as inhibitors for some subtypes
of BoNT/B and LC activators for other subtypes.
The extraction efficiency experiments also shed some
light on the interaction of these mAbs with the different
BoNT/B subtypes. Three mAbs which had poor extrac-
tion efficiency were 1B10.1, 1B22.4, and B1.1. Because
the inhibitory experiments showed that the mAbs
1B10.1 and 1B22.4 inhibited the enzymatic activity of
BoNT/B, the decreased cleavage products after extrac-
tion with these mAbs were likely due to inhibition of
activity rather than poor extraction efficiency. In con-
trast, the mAb B1.1 was a moderate to strong LC activa-
tor in the antibody inhibitory study but was one of the
worst mAbs for extracting all five BoNT/B subtypes
tested. This could be attributed to the relatively low affi-
nity of mAb B1.1 for BoNT/B, or it may reflect either
poor coupling of the mAb to the beads or inactivation
of the mAb upon coupling.
Additionally, the extraction efficiency experiments
demonstrated that some mAbs work very well for most
subtypes, but not all of them. For example, mAb B11E8
yielded the highest or second highest response in terms
of activity for BoNT/B1, /B2, /B3, and /B5, but was one
of the worst choices for BoNT/B4. This mAb was not
inhibitory for the activity of BoNT/B4; rather, this mAb
0
0.5
1
1.5
2
2.5
Figure 4 A graph indicating the % of inhibition in activity of BoNT/B3 (green), /B4 (purple), and /B5 (blue)following incubation with
the mAb panel. The sample with no antibody had no inhibition of activity, so the % of inhibition in activity is calculated by dividing the peak
area ratio of the peptide cleavage product over the internal standard peptide of the individual antibody by the peak area ratio of the sample
with no antibody.
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Page 8 of 11has no affinity for BoNT/B4 compared to the other
subtypes.
The Endopep-MS assay relies upon mAb extraction of
BoNT from a clinical or food sample as a sample pre-
paration step before analysis for the toxin, so high affi-
nity, non-inhibitory mAbs are critical components of
the assay. Additionally, mAbs that activate the enzy-
matic activity of the toxin after binding may further
improve the sensitivity of detection in the Endopep-MS
assay. Therefore, it is important to assess the binding
affinities and potential enzymatic inhibition abilities of
mAbs against a variety of BoNT subtypes within the
chosen serotype before choosing mAbs for extraction.
This assessment of a large panel of monoclonal BoNT/B
antibodies should enable us to identify an antibody or a
few mAbs that demonstrate strong extraction efficiency
for all known BoNT/B, which currently includes the
BoNT/B1-/B6 subtypes, without inhibiting the enzy-
matic activity of the toxin.
After testing a panel of 24 fully human antibodies
against all BoNT/B subtypes in our possession, BoNT/
B1-/B5, and examining both their inhibitory ability as
well as their extraction efficiency, mAbs that had good
results with all five subtypes were mAbs 1B18.1, 2B18.1,
2B18.2, 2B18.3, B12.2, and 2B23. Four of these mAbs
(1B18.1, 2B18.1, 2B18.2, and 2B18.3) are clonally related,
having almost the same HC variable regions and differ-
ent LC variable regions, and binding to the same HN
epitope. Antibodies interacting with all three domains of
the toxin were represented, as B12.2 bound to the HC
and 2B23 bound to the LC. It is known that using mul-
tiple mAbs which bind non-overlapping epitopes
increases the effective affinity for the toxin by as much
as 200-fold over the affinity of the individual antibodies
[15]. Use of multiple mAbs binding different epitopes
not only increases overall binding affinity, which is
important for toxin extraction, but also offers a unique
opportunity to design a mixture of mAbs that effectively
bind a variety of epitopes, including regions that are
conserved across the BoNT/B subtypes and also regions
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Figure 5 Mass spectra of the Endopep-MS botulinum
neurotoxin B1 reaction after extraction of the toxin with mAb
B12.2 (5A), no antibody (5B), or mAb B1.1 (5C). The peptide
cleavage product indicates the presence of BoNT/B in 5A and 5B,
but not 5C, at m/z 1759.9 and the internal standard is present in all
spectra at m/z 1766.9.
Table 4 Peak area ratios of the peptide cleavage product
divided by the internal standard peptide obtained from
the Endopep-MS reaction of BoNT B after its extraction
by the antibody panel.
Antibody BoNT/B1 BoNT/B2 BoNT/B3 BoNT/B4 BoNT/B5
None 1.02 1.62 0.46 0.14 1.26
B11E8 4.03 1.68 5.71 0.002 1.84
1B12.3 3.58 1.68 4.31 0.09 1.85
2B18.2 3.47 1.25 5.58 0.29 1.60
B8.1 3.30 1.44 0.54 0.14 0.009
B12.2 3.30 1.70 4.14 0.15 1.35
2B30 3.21 1.27 4.44 0.002 1.35
B12.1 3.18 1.89 5.51 0.19 1.65
1B18.1 3.14 1.23 4.98 0.19 1.51
2B18.3 3.14 1.17 5.14 0.17 1.39
2B18.1 3.04 1.15 3.94 0.22 1.62
1B12.4 2.92 1.11 3.35 0.13 2.26
2B24 2.76 1.01 2.93 0.19 1.60
2B23 2.68 1.18 3.24 0.11 1.19
2B25.1 2.38 0.72 1.69 0.05 0.69
A12 2.36 1.47 0.99 0.12 0
B6.1 2.35 1.12 3.16 0.15 1.51
4B19.1 2.31 1.25 3.93 0.21 2.11
6A12 1.39 1.09 2.50 0.07 1.18
1B22 0.95 0.72 3.79 0.03 0.95
2B27 0.92 0.56 1.29 0.05 1.12
2B29 0.88 0.80 1.90 0.03 0.87
1B22.4 0.54 0.21 0.32 0.009 0.06
B1.1 0000 0.002
1B10.1 0000 0.11
Five different subtypes of BoNT/B were used, and they include /B1, /B2, /B3,
/B4, and /B5.
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Page 9 of 11that may represent high-affinity binding sites for only a
portion of the toxin subtypes. These multiple antibodies
help to ensure that each toxin subtype will be recog-
nized and extracted. As new BoNT/B subtypes are dis-
covered, amino acid mutations affecting binding
epitopes may be present. The use of multiple mAbs that
recognize a variety of epitopes minimize the impact of
these mutations, increasing confidence that all BoNT/B
subtypes will be efficiently extracted.
1B18.1, 2B18.1, 2B18.2, and 2B18.3 bound the same
epitope in the translocation domain. Examining their
results in the extraction assay presented here, we found
that 2B18.2 yielded the best overall results for subtypes
BoNT/B1-/B5. Because of this, we are opting to use
2B18.2 as one of the mAbs for extraction of BoNT/B1-/
B5 from sample matrices before analysis with the Endo-
pep-MS method. Among the final list of mAbs which
yielded excellent extraction results with all five subtypes
tested, there were two binding unique epitopes which
could be used: B12.2 and 2B23. B12.2 had better perfor-
mance than 2B23, so we are opting to use B12.2, direc-
ted against the receptor binding portion of the HC, as a
second mAb for extraction of BoNT/B1-/B5 from sam-
ple matrices before analysis with the Endopep-MS
method. Unfortunately, Bo N T / B 6 ,t h eo n l yo t h e rc u r -
rently known BoNT/B subtype, was not available to us
for testing. However, the sequence of BoNT/B6 for the
epitope bound by 2B18.2 is completely conserved, so it
would be anticipated that 2B18.2 could efficiently
extract BoNT/B6 [19].
Conclusions
In addition to determining the best mAbs for sample
preparation before Endopep-MS, this work determined
in vitro inhibition abilities of a panel of mAbs against
BoNT/B1-/B5. Many mAbs showed similar results with
BoNT/B1-/B5, but in some cases they differed, indicat-
ing differing toxin extraction efficiencies due to differing
binding affinities or inhibition of toxin activity. In some
cases, activation of toxin LC activity was seen. These
findings indicate that mAb choice is crucial to the abil-
ity of these types of assays to sensitively detect a diverse
range of BoNT/B toxin subtypes, which is a critical first
step to providing proper treatment in a timely manner.
In addition, these mAb characterizations have the
potential to assist with mechanistic studies of BoNT/B
protection and treatment, which is important for study-
ing alternative therapeutics for botulism.
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